Fintech

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Globenewswire·March 30, 2026 at 11:30 AM

Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 ...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

NY Fed: Mobile Sports Betting Increases Credit Delinquency
PYMNTS
Labor Department Eases 401(k) Alternative Investment Access
PYMNTS
US rule may open trillions in 401(k) to crypto
CoinDesk
Businesses Adapt AI Budgeting to Usage-Based Pricing
PYMNTS

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

NY Fed: Mobile Sports Betting Increases Credit Delinquency

Labor Department Eases 401(k) Alternative Investment Access

US rule may open trillions in 401(k) to crypto

Businesses Adapt AI Budgeting to Usage-Based Pricing